Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target Lowered to $1.50 at Mizuho

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price target reduced by Mizuho from $3.00 to $1.50 in a research report released on Wednesday,Benzinga reports. They currently have an outperform rating on the biotechnology company’s stock.

Other analysts have also issued research reports about the company. Guggenheim cut their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research note on Friday, November 15th. HC Wainwright cut their price objective on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research note on Thursday, November 14th. Finally, StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $2.79.

Adaptimmune Therapeutics Stock Down 0.6 %

ADAP stock opened at $0.72 on Wednesday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.82 and a current ratio of 3.85. The company has a market cap of $184.41 million, a P/E ratio of -3.28 and a beta of 2.26. The stock’s 50 day simple moving average is $0.80 and its 200 day simple moving average is $1.00. Adaptimmune Therapeutics has a fifty-two week low of $0.43 and a fifty-two week high of $2.05.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ADAP. Long Focus Capital Management LLC raised its position in Adaptimmune Therapeutics by 15.6% during the 2nd quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock valued at $12,037,000 after purchasing an additional 1,662,184 shares during the last quarter. Baillie Gifford & Co. increased its stake in shares of Adaptimmune Therapeutics by 10.7% during the third quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after buying an additional 1,626,657 shares during the period. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics during the third quarter valued at approximately $95,000. Renaissance Technologies LLC raised its holdings in shares of Adaptimmune Therapeutics by 28.3% during the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock valued at $1,742,000 after acquiring an additional 394,566 shares in the last quarter. Finally, Vontobel Holding Ltd. lifted its stake in Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock worth $41,000 after acquiring an additional 30,000 shares during the period. 31.37% of the stock is currently owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.